Abstract 504P
Background
It is proved that anaplastic lymphoma kinase-rearranged non–small-cell lung cancer (ALK-rearranged NSCLC) is sensitive to ALK inhibitors while the chemotherapy resistance is unavoidable. In this study, safety and antitumor activity of the novel ALK inhibitor (ALKi) CT-707 is evaluated in Chinese patients with advanced ALK-rearranged NSCLC.
Methods
This Multi-center, open-label phase I study (NCT02695550) recruited adult patients with ALK-rearrangement (confirmed by fluorescence in situ hybridization and/or immunohistochemistry) of locally advanced/metastatic malignancies including non–small-cell lung cancer. This study consisted of a dose escalation study and a dose expansion study. CT-707 was administered orally once a day for 21 days. The Lung Cancer Center of Peking Union Medical College Hospital of Chinese Academy of Medical Sciences summarized the safety and effectiveness of the cases enrolled in this center.
Results
Thirteen patients who were treated with CT-707 from 450 to 600mg (in the dose increasing phase) were enrolled in this trial (two patients were previously treated with crizotinib). Twelve patients were diagnosed with lung adenocarcinoma and one patient was malignant pleural mesothelioma. After treatment, grade 3 diarrhea (600 mg QD) was found as dose-limiting toxicity (DLT). The most common adverse events included diarrhea (92%), elevated aspartate aminotransferase (61%), elevated alanine aminotransferase (54%), hair loss (38%), and vomiting (31%).ORR and disease control rate among patients were 10 of 13 (77%) and 11 of 13 (85%). The median progression-free survival was 13 months (95% CI:9.98-16.00).The overall survival rate of 12 months was 85%, which has not yet reached the median overall survival. Among all patients, ten patients observed partial response (PR). One patient reached a complete response (CR). However, no response of the disease was observed in patients with malignant pleural mesothelioma.
Conclusions
CT-707 is effective in Chinese patients with tumors harboring ALK rearrangements. It has reliable safety and tremendous clinical application value.
Clinical trial identification
NCT02695550; March 2016.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract